AACR
The firm shared performance study results at a recent meeting and said it has begun processing samples for its first major pharma customer.
Companies including Bruker, Akoya, and Standard BioTools either released new platforms or highlighted advances in their systems' capabilities at the meeting.
At the AACR annual meeting, both companies shared new data on their technologies' performance in detecting early and late-stage cancers.
New Epigenomic Biomarker Could Predict CAR T-Cell Therapy Resistance in Advanced Childhood Leukemia
Premium
At AACR, researchers described how pediatric ALL patients who don't respond to anti-CD19 CAR T-cell therapy have cancers with a unique, stem cell-like epigenome.
C2i Genomics Lays Groundwork for Global Launch of Whole-Genome Minimal Residual Disease Test
Premium
With EU lab partnerships and a newly announced CE mark, the company is poised for the first clinical implementations of its solid tumor residual disease test.